

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. | | |
|---|----------------|----------------------|-------------------------|------------------|--|----------|
| 09/450,609 | 11/30/1999 | HELLE WEIBEL | 5739.200-US | 7926 | | |
| 7: | 590 09/24/2003 | | | | | |
| STEVE T ZELSON ESQ | | | EXAMI | EXAMINER | | |
| NOVO NORDISK OF NORTH AMERICA INC 405 LEXINGTON AVENUE SUITE 6400 NEW YORK, NY 101746400 | | | KIM, JENNIFER M | | | |
| | | | | | | ART UNIT |
| | | | , | • • | | 1617 |
| | | | DATE MAILED: 09/24/2003 | 2/7 | | |

Please find below and/or attached an Office communication concerning this application or proceeding.

| | | Applicatio | n No | Applicant(s) | | | | | |
|---|--|-------------------|--|-------------------------------|-----|--|--|--|--|
| . — | | | | • | | | | | |
| | Office Action Summany | 09/450,60 | 9 | WEIBEL ET AL. | | | | | |
| | Office Action Summary | Examin r | | Art Unit | | | | | |
| | The MAN INO DATE of this communication and | Jennifer k | | 1617 | l-l | | | | |
| The MAILING DATE of this communicati n appears on the cover sheet with the c rrespondence address Period for Reply | | | | | | | | | |
| A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status | | | | | | | | | |
| 1)⊠ | Responsive to communication(s) filed on <u>24 July 2003</u> . | | | | | | | | |
| 2a)⊠ | ☑ This action is FINAL. 2b) ☐ This action is non-final. | | | | | | | | |
| 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. | | | | | | | | | |
| Disposition of Claims | | | | | | | | | |
| - | 4)⊠ Claim(s) 6,7,9,12,13,16 and 28 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. | | | | | | | | |
| | 5) Claim(s) is/are allowed. | | | | | | | | |
| 6)⊠ Claim(s) <u>6,7,9,12,13,16,28</u> is/are rejected. | | | | | | | | | |
| · | 7)⊠ Claim(s) <u>29-31</u> is/are objected to. | | | | | | | | |
| · · · · | Claim(s) are subject to restriction and/or | r election re | auirement. | | | | | | |
| Application Papers | | | | | | | | | |
| 9) The specification is objected to by the Examiner. | | | | | | | | | |
| 10)[| The drawing(s) filed on is/are: a)□ accep | oted or b) | objected to by the Exan | niner. | | | | | |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). | | | | | | | | | |
| 11) 🗌 . | The proposed drawing correction filed on | _ is: a) <u> </u> | proved b) disappro | ved by the Examin | er. | | | | |
| If approved, corrected drawings are required in reply to this Office action. | | | | | | | | | |
| 12)☐ The oath or declaration is objected to by the Examiner. | | | | | | | | | |
| Priority under 35 U.S.C. §§ 119 and 120 | | | | | | | | | |
| 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). | | | | | | | | | |
| a) | a)⊠ All b)□ Some * c)□ None of: | | | | | | | | |
| | 1.⊠ Certified copies of the priority documents have been received. | | | | | | | | |
| | 2. Certified copies of the priority documents have been received in Application No | | | | | | | | |
| * 5 | 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. | | | | | | | | |
| 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). | | | | | | | | | |
| a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. | | | | | | | | | |
| Attachment(s) | | | | | | | | | |
| 2) 🔲 Notic | e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) | | 4) Interview Summary 5) Notice of Informal P 6) Other: . | (PTO-413) Paper Notation (PTo | | | | | |

Art Unit: 1617

DETAILED ACTION

The amendment filed July 24, 2003 have been received and entered into the application.

Claim Rejections - 35 USC § 103

- **1.** The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 6, 7, 9, 12, 13, 16, and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lohray et al.(WO 9741097).

Lohray et al. teaches at page 35, example, applicants' composition in a tablet form. Lohray et al. at page 34, lines 27-29, page 35, example, and page 7, lines 13-14, teach pharmaceutical composition containing applicants' active agent in tablet, capsule, or powder form, in combination with the pharmaceutically acceptable excipient set forth in claim 6, and flavourants, sweeteners set forth in claim 16, and other media normally employed in preparing such compositions. Lohray et al. teach that the above composition typically contains from 1 to 20% by weight of active compound, and the

Art Unit: 1617

reminder of the composition being pharmaceutically acceptable carrier, diluents or solvents. (page 35, lines 1-3).

Lohray et al. do not expressly teach the low water content comprising anhydrouse lactose and specifiec cellulose set forth in claim 6 and proportions of excipients set forth in claim 9.

It would have been obvious to one of ordinary skill in the art to modify Lohray composition to employ any form of lactose (e.g. anhydrose lactose) because Lohray et al. teach the composition comprising lactose in general. One would have been motivated to employ any form of lactose as taught by Lohray to provide a pharmaceutical composition containing the active agent for the effective treatment of diabetics because lactose as utilized in Lohray composition encompasses any lactose form including anhydrous lactose as claimed by the Applicants. The proportions of active agents to be used set forth in claim 9 and specified cellulose set forth in claim 6 are deemed obvious because it is within the knowledge of the skilled pharmacologist to optimize the range of amounts of active agents and the excipients to be utilized. Moreover, Lohray et al. teach the ranges of 1-20% as being an active compound and the remainder of the composition being pharmaceutically acceptable carriers, diluents or solvents. One of ordinary skill in the art would optimize this range of excipients within the range of about 20-80% as taught by Lohray et al. Further, Lohray et al. utilize one of cellulose derivative (e.g. carboxymethyl cellulose) as useful excipient and have a viable utility as an excipient which is so closely related to microcrystalline cellulose utilized claimed by the Applicants and it is to be chemically obvious thereform (cellulose

Art Unit: 1617

derivatives) in the absence of any unobvious or unexpected properties especially since one of ordinary skill in the art would expect that compounds so closely related chemically would have the same or essentially the same properties.

For these reasons the claimed subject matter is deemed to fail to patentably distinguish over the state of the art as represented by the cited references. The claims are therefore properly rejected under 35 U.S.C. 103.

Sohda reference is withdrawn as a reference in view of Applicants' amendment.

Allowable Subject Matter

Claims 29-31 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Response to Arguments

Applicants arguments filed July 24, 2003 have been fully considered but they are not persuasive. Applicants argue that there is absolutely no suggestion or discussion in Lohray regarding the desirability of low water content in excipients and it would have not been obvious to consider using anhydrous lactose and/or cellulose with low water

Page 5

Application/Control Number: 09/450,609

Art Unit: 1617

content. This is not persuasive because claim 6 is drawn to a pharmaceutical composition comprising the active agents and excipients such as anhydrous lactose, microcrystalline cellulose, magnesium stearate, and talc. The composition taught by Lohrey encompasses Applicants' composition set forth in claim 6 because as admitted by the Applicants that in the production of Lohray composition, the active ingredient and lactose are moistened or they were blended with water, therefore it would be likely that Lohray composition used the anhydrous lactose in order to moisten or blended the active compounds with water. Further, Lohrey composition comprises Lactose which encompasses Applicants' anhydrous lactose as well. Applicants' clarification of the Declaration filed with the response filed on August 23, 2002 is noted. However, formulations of A-B do not differ from the composition taught by Lohrey reference because Lohrey composition comprising Lactose encompasses anhydrous lactose. Applicants assert that the Sohda reference would not add anything further to the disclosure of Lohray and that Sohda et al. is directed to completely different class of compounds, 2,4-oxazolidinedione compounds. This argument is moot in view of Applicants' amendment to cancel claims 14 and 15, claims drawn to combination with anti-oxidants. For these reasons the claimed subject matter is deemed to fail to patentably distinguish over the state of the art as represented by the cited references. The claims are therefore properly rejected under 35 U.S.C. 103.

Art Unit: 1617

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Kim whose telephone number is 703-308-2232. The examiner can normally be reached on Monday through Friday 6:30 am to 3 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 703-305-1877. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Art Unit: 1617

Page 7

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-

1235.

Sreenivasan Padmanabhan Supervisory Examiner

Art Unit 1617

jmk

September 15, 2003